metreleptin 5 MG/ML Injectable Solution [Myalept]

What the CMS Formulary Data Shows for metreleptin 5 MG/ML Injectable Solution [Myalept]

Per the CMS 2026 Part D formulary file, metreleptin 5 MG/ML Injectable Solution [Myalept] (RxNorm concept RXCUI 1491634, generic name metreleptin) appears on 14 distinct formulary files spanning 106 Medicare Part D plan offerings - 2.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 2 to Tier 5, with a cross-plan average of Tier 4.6.

Real-world access to metreleptin 5 MG/ML Injectable Solution [Myalept] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 21.4% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 13 Part D beneficiaries filled metreleptin 5 MG/ML Injectable Solution [Myalept] in 2023, with total plan-and-beneficiary spending of $17,122,465 and an average per-beneficiary annual cost of $1,317,112.68. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry metreleptin 5 MG/ML Injectable Solution [Myalept] today.